Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Real-world Study Exploring the Guidance of FES-PET for First-line Treatment of HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer Patients

NCT06655545 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06655545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06655545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Real-world Study Exploring the Guidance of FES-PET for First-line Treatment of HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer Patients
Lead sponsor
Fudan University
Phase
Observational
Overall status
Completed
Start date
July 15, 2023
Completion date
February 1, 2025
Enrollment
473 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer